---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000030"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-05-15T12:02:37+00:00"
generated_at: "2026-05-15T12:06:03.580960+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma reports $68.3M cash; plans Phase 3 for efzofitimod after FDA meeting

## Summary
- Cash, cash equivalents, restricted cash and investments: $68.3M as of March 31, 2026.
- Plans to file IND in June 2026 for a Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease; primary endpoint FVC at week 48.
- Phase 3 study to enroll ~372 patients; randomized, double-blind, placebo-controlled, 54 weeks.
- On track to complete enrollment in Phase 2 EFZO-CONNECT study for SSc-ILD in first half 2026.
- R&D expenses $7.3M and G&A expenses $4.1M for Q1 2026.

## SEC filing metadata
- accession: 0001339970-26-000030
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-05-15T12:02:37+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/0001339970-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/atyr-20260515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000030
- JSON: https://secwatch.observer/filing/0001339970-26-000030.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000030.txt

## Key facts
- Earnings Releases
  aTYR PHARMA INC reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 15, 2026, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000030/0001339970-26-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.